Second quarter development in the portfolio company Vitrolife is also pleasing to note. Year to date Vitrolife's share price has increased by circa 70 per cent. One new feature in this report is that we have chosen to present MedCap as a portfolio company. Today Bure is MedCap's single largest shareholder and we take part in the company's board work. In conclusion, at the end of the period Bure had more than SEK 700M in investable assets and I see it as one of my foremost tasks to maintain a high level of activity in working with new investments. Henrik Blomquist Acting CEO